News

At week 24, patients receiving guselkumab had significant decreases in C-reactive protein and effector cytokines linked to the interleukin-23 (IL-23)/IL-17 levels compared with patients in the placebo cohort.

Although gout was not associated with hearing loss, hyperuricemia was significantly linked to impairment.

Osteoporosis is estimated to affect 595 million patients worldwide, representing a 132% increase in total cases since 1990.

Guidelines aim to help the identification of ILD in patients with rheumatic disease and aid in improving the management of patients.

Patients with fibromyalgia reported poorer subjective sleep quality compared with controls, although accelerometry parameters showed no significant differences between groups.

Findings demonstrated Danggui Niantong Decoction combined with conventional Western medicine was more effective in treating gout than Western medicine alone.

Researchers report on the global real-world safety profile of tofacitinib in psoriatic arthritis.

Although patients in both the intervention and control cohorts gained weight, patients treated with glucocorticoids gained an average of 1.1 kg more than controls.

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

Granted to Ipsen, the breakthrough treatment reduces new, abnormal bone growth in people living with the ultra-rare bone disease.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

The patient-specific definition of gout remission included minimal symptoms, the absence of dietary restrictions, and management strategies to maintain remission.

This follow-up of the MIRROR trial demonstrates significant benefits of coadministration of methotrexate with pegloticase, maintaining the initial findings from observations through 6 months.

Fibromyalgia symptoms were reduced at both 4 and 12 weeks in patients receiving tocilizumab treatment.

The analysis suggested a causal relationship between increased tea intake and overall reduced risk of gout in all 3 gout datasets.

A significantly higher number of total outpatient clinic visits was observed in patients with fibromyalgia compared to controls.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

A cross-sectional analysis showed the reliability and repeatability of the Polish version of the Fibromyalgia Impact Questionnaire were "very good."

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.

The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).

Common themes among patients and parents included a need to accurately assess pain and offer non-pharmacological options for pain management.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases when compared with controls.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.

The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.